Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
106 Results for "
complement inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (106)
106 Results for "complement inhibitor" in MCE Product Catalog:
13
13 Publications Verification
Synonyms: LNP023
Target:
Research Areas:
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
13
13 Publications Verification
Synonyms: LNP023 hydrochloride
Target:
Research Areas:
Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
7
Target:
Research Areas:
7
Target:
Research Areas:
7
Target:
Research Areas:
5
5 Cited Publications
Synonyms: DSS (MW 5000); DXS (MW 5000)
5
Target:
Research Areas:
Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
5
Target:
Research Areas:
Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
5
5 Cited Publications
Target:
Research Areas:
JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 μM) and reduces TNF levels (EC50=4.5 μM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases .
4
4 Cited Publications
Cat. No.: HY-P9914
CAS No.: 219685-50-4
Synonyms: Anti-Human C5, Humanized Antibody; h5G1.1
Target:
Research Areas:
Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology
3
3 Cited Publications
Cat. No.: HY-P1036
CAS No.: 206645-99-0
Target:
Research Areas:
3
3 Cited Publications
Cat. No.: HY-P1036A
Target:
Research Areas:
2
2 Cited Publications
Cat. No.: HY-N9481
CAS No.: 56411-57-5
2
2 Cited Publications
Cat. No.: HY-A0183
CAS No.: 1446756-47-3
Synonyms: Phospholipids, phosphatidylserines; Serine glycerophosphatides
Category:
Target:
2
2 Cited Publications
Synonyms: ALXN2050; ACH 0145228; ACH-5228
Target:
Research Areas:
Vemircopan (ALXN2050) is an orally active complement factor D (FD) inhibitor. Vemircopan can be used in the research of diseases such as myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria .
1
1 Cited Publications
Cat. No.: HY-P3252A
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P9976
CAS No.: 1461640-62-9
Synonyms: ch38SB19; hu38SB19; SAR-650984
1
1 Cited Publications
Cat. No.: HY-P9976A
CAS No.: 1461640-62-9
1
Target:
Research Areas:
1
1 Cited Publications
Target:
Research Areas:
Compound C5-IN-1 (Compound 7) is a selective allosteric inhibitor of complement component protein C5. Compound C5-IN-1 prevents C5 from being cleaved by C5 convertase, inhibits the cleavage of C5 into C5a and C5b, and thus blocks the formation of membrane attack complex (MAC). Compound C5-IN-1 has an IC50 of 0.77 μM and 5 nM in 50% human whole blood and 2% human serum to block MAC deposition induced by zymosan, respectively. Compound C5-IN-1 can be used to study diseases related to complement overactivation, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
